Drug Profile
NYX 783
Alternative Names: NYX-783Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Aptinyx
- Developer Aptinyx; Yale University
- Class Antidepressants; Anxiolytics; Peptides; Small molecules
- Mechanism of Action NMDA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Opioid-related disorders
- No development reported Alcoholism
- Discontinued Post-traumatic stress disorders
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Alcoholism in USA (PO)
- 03 May 2023 Discontinued - Phase-II/III for Post-traumatic stress disorders in USA (PO)
- 06 Apr 2023 Aptinyx terminates phase II/III trial in Post-traumatic stress disorders in USA (PO) (NCT05181995)